Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.49 |
| ▸ | GALR2 | O43603 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8932207 | 0.84 | EGFR (0.50) | EGFRGALR2LMNAPOLBABCG2 | |
| SCHEMBL8932196 | 0.83 | EGFR (0.60) | EGFRGALR2LMNAPOLBABCG2 | |
| SCHEMBL28622128 | 0.82 | EGFR (0.41) | EGFRABCG2FBP1 | |
| SCHEMBL17538470 | 0.81 | MAPT (0.40) | EGFRLMNAPOLBABCG2FBP1 | |
| SCHEMBL8932198 | 0.81 | EGFR (0.64) | EGFRGALR2LMNAPOLBABCG2 | |
| SCHEMBL26321 | 0.80 | EGFR (0.64) | EGFRABCG2FBP1 | |
| SCHEMBL159918 | 0.80 | EGFR (0.52) | EGFRABCG2FBP1 | |
| SCHEMBL19100039 | 0.80 | S1PR2 (0.49) | EGFRLMNAABCG2FBP1 | |
| SCHEMBL27410247 | 0.80 | IRAK4 (0.52) | EGFRLMNATYK2 | |
| SCHEMBL4579035 | 0.79 | EGFR (0.51) | EGFRPOLBABCG2FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187459-B2 | Quinazoline-7-ether compounds and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140221406-A1 | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| CN-103237801-A | Quinoline or quinazoline derivatives having apoptosis-inducing activity on cells | HANMI HOLDINGS CO LTD | 2013-08-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221406-A1 | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | ABL1, ERBB4, ERBB2 | EGFR 5/4885GALR2 2563/4885LMNA 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.